Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Inflammatory Bowel Disease Treatment Market, by Type
1.4.2 North America Inflammatory Bowel Disease Treatment Market, by Distribution Channel
1.4.3 North America Inflammatory Bowel Disease Treatment Market, by Route of Administration
1.4.4 North America Inflammatory Bowel Disease Treatment Market, by Drug Class
1.4.5 North America Inflammatory Bowel Disease Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Approvals and Trials : 2017, Aug – 2021, Sep) Leading Players
Chapter 4. North America Inflammatory Bowel Disease Treatment Market by Type
4.1 North America Crohn's Disease Market by Country
4.2 North America Ulcerative Colitis Market by Country
Chapter 5. North America Inflammatory Bowel Disease Treatment Market by Distribution Channel
5.1 North America Hospital Pharmacy Market by Country
5.2 North America Retail Pharmacy Market by Country
5.3 North America Online Pharmacy Market by Country
Chapter 6. North America Inflammatory Bowel Disease Treatment Market by Route of Administration
6.1 North America Injectable Market by Country
6.2 North America Oral Market by Country
Chapter 7. North America Inflammatory Bowel Disease Treatment Market by Drug Class
7.1 North America TNF inhibitors Market by Country
7.2 North America Anti-integrin Market by Country
7.3 North America IL inhibitors Market by Country
7.4 North America Corticosteroids Market by Country
7.5 North America JAK inhibitors Market by Country
7.6 North America Aminosalicylates Market by Country
7.7 North America Others Market by Country
Chapter 8. North America Inflammatory Bowel Disease Treatment Market by Country
8.1 US Inflammatory Bowel Disease Treatment Market
8.1.1 US Inflammatory Bowel Disease Treatment Market by Type
8.1.2 US Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.1.3 US Inflammatory Bowel Disease Treatment Market by Route of Administration
8.1.4 US Inflammatory Bowel Disease Treatment Market by Drug Class
8.2 Canada Inflammatory Bowel Disease Treatment Market
8.2.1 Canada Inflammatory Bowel Disease Treatment Market by Type
8.2.2 Canada Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.2.3 Canada Inflammatory Bowel Disease Treatment Market by Route of Administration
8.2.4 Canada Inflammatory Bowel Disease Treatment Market by Drug Class
8.3 Mexico Inflammatory Bowel Disease Treatment Market
8.3.1 Mexico Inflammatory Bowel Disease Treatment Market by Type
8.3.2 Mexico Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.3.3 Mexico Inflammatory Bowel Disease Treatment Market by Route of Administration
8.3.4 Mexico Inflammatory Bowel Disease Treatment Market by Drug Class
8.4 Rest of North America Inflammatory Bowel Disease Treatment Market
8.4.1 Rest of North America Inflammatory Bowel Disease Treatment Market by Type
8.4.2 Rest of North America Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.4.3 Rest of North America Inflammatory Bowel Disease Treatment Market by Route of Administration
8.4.4 Rest of North America Inflammatory Bowel Disease Treatment Market by Drug Class
Chapter 9. Company Profiles
9.1 Allergan PLC (AbbVie)
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Approvals and Trials:
9.2 Johnson & Johnson
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental &Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.5.2 Approvals and Trials:
9.3 Merck Group
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Acquisitions and Mergers:
9.3.5.3 Product Launches and Product Expansions:
9.4 Amgen, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expenses
9.4.5 Recent strategies and developments:
9.4.5.1 Partnerships, Collaborations, and Agreements:
9.4.5.2 Acquisitions and Mergers:
9.4.5.3 Geographical Expansions:
9.4.5.4 Approvals and Trials:
9.5 Eli Lilly and Company
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional Analysis
9.5.4 Research & Development Expense
9.6 Biogen, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Product Launches and Product Expansions:
9.6.5.3 Approvals and Trials:
9.7 Pfizer, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Acquisitions and Mergers:
9.7.5.2 Approvals and Trials:
9.8 Novartis AG
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Acquisitions and Mergers:
9.8.5.3 Approvals and Trials:
9.9 Takeda Pharmaceutical Company Limited
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Partnerships, Collaborations, and Agreements:
9.9.5.2 Acquisitions and Mergers:
9.9.5.3 Product Launches and Product Expansions:
9.9.5.4 Approvals and Trials:
9.10. UCB S.A.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Regional Analysis
9.10.4 Research & Development Expense
9.10.5 Recent strategies and developments:
9.10.5.1 Partnerships, Collaborations, and Agreements:
9.10.5.2 Approvals and Trials:
Unique Offerings 